Business
Admission to AIM and First Day of Dealings
Admission to AIM and First Day of Dealings.
About this update from Trellus Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1126A\n Trellus Health PLC\n 28 May 2021\n \n \n \n \n \n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE READER'S ATTENTION IS DRAWN TO THE DISCLAIMER AT THE END OF THIS ANNOUNCMENT.\n \n \n Capitalised terms used in this announcement have the same meanings\nas in the Company's Admission Document, unless specified otherwise\n \n Trellus Health plc\n (\"Trellus Health\" or the \"Company\")\n \n Admission to trading on AIM\n & First Day of Dealings\n \n LONDON, UK. AND NEW YORK, U.S. (28 May 2021). Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, announces that admission to trading on AIM (\"Admission\") will take place and dealings will commence at 8.00 a.m. today under the ticker TRLS and ISIN GB00BNNFM402.\n \n \n The Company's Admission Document is\n available here: \n \n www.trellushealth.com/investors\n \n \n \n Summary and Highlights:\n \n · Successful Fundraising for gross proceeds of £28.5 million\n \n · Issue price per Trellus Share of 40 pence\n \n · The Fundraising was significantly oversubscribed across all components, raising the following amounts in gross proceeds:\n \n − the Placing (c. £25.2 million)\n \n − the Subscription (c. £2.4 million)\n \n − the Restricted Offer (c. £0.9 million)\n \n · Market capitalisation of approximately £64.6 million on Admission\n \n · Enlarged Share Capital on Admission of 161,475,000 Ordinary Shares\n \n · The 71,250,000 New Ordinary Shares represent 44.1 per cent. of the Enlarged Share Capital\n \n · \n N+1 Singer acted as Sole Bookrunner in relation to the Placing and is acting as the Company's Nominated Adviser and Corporate Broker from Admission\n \n Use of Proceeds\n The net proceeds of the Fundraising are intended to be used:\n \n \n · to pay amounts due under the ISMMS licence agreement;\n \n · to continue the development and enhancement of the TrellusElevateTM platform, including developing the conversational artificial intelligence tec...